AHA Coding Clinic® for ICD-9 - 2009 Quarter 4; VOLUMES 1 & 2 NEW/REVISED CODES
Tumor Lysis Syndrome
A 12-year-old child had been recently diagnosed with acute myeloid leukemia. He was admitted to the hospital for chemotherapy. On the first day of admission, chemotherapy was administered. During the hospitalization, the child complained of weakness and lethargy. His laboratory work-up revealed hyperkalemia, abnormal uric acid levels, hyperphosphatemia, and elevated lactate dehydrogenase (LDH). Based on these findings, the provider diagnosed tumor lysis syndrome secondary to antineoplastic therapy. How should this case be coded? ...
Subscribe or sign in to view the full article.
Article Overview
This coding article reviews tumor lysis syndrome as a clinically significant metabolic complication associated with cancer treatment and, more rarely, spontaneous onset. It is written for coding professionals who need to understand the ICD-9-CM update, the clinical context of the condition, and the general documentation considerations discussed in the article.
Why This Topic Matters
Accurate identification of tumor lysis syndrome affects diagnosis coding, especially when the condition occurs in the setting of antineoplastic therapy or as a spontaneous event. The article also addresses related coding context for the cause of the condition in drug-induced cases and the way the topic was added to ICD-9-CM.
What You Will Learn
- How tumor lysis syndrome is characterized in a coding and clinical context
- Why the ICD-9-CM update for this condition matters
- What types of circumstances are associated with the syndrome
- What general coding considerations are mentioned for cases involving treatment-related causes
Who Should Read This
- Medical coders
- Coding auditors
- Clinical documentation staff
- Revenue cycle professionals
Codes Discussed
Code Ranges Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com